A tyrosine phosphatase SHP2 gain-of-function mutation enhances malignancy of breast carcinoma
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2576 views | HTML 2282 views | ?
Zhongqian Hu1,2,* Xinyi Wang1,3,* Haoshu Fang1, Yakun Liu1, Danlei Chen1, Qian Zhang1, Xia Liu1, Daoyan Wei1, Chengkui Qu1,4, Siying Wang1
1 Department of Pathophysiology, Anhui Medical University, Hefei 230032, China
2 Department of Ultrasound, Zhongda Hospital, Southeast University, Nanjing 210009, China
3 Department of Clinical Medicine, Anhui Medical University, Hefei 230032, China
4 Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta 30322, GA, USA
* These authors have contributed equally to this work
Siying Wang, e-mail: [email protected]
Keywords: breast cancer, SHP2, D61G mutation, tumor, gain-of-function
Received: June 25, 2015 Accepted: November 25, 2015 Published: December 10, 2015
Background: Evidence suggests that Src homologous protein phosphotyrosyl phosphatase 2 (SHP2) mutations promote cancer development in several solid tumours. In this study, we focused on the in vivo and in vitro effects of an SHP2 mutation on the breast cancer phenotype to determine whether this mutation is correlated with a malignant phenotype.
Methods: Mutant PTPN11 cDNA (D61G) was transduced into MDA-MB231 and MCF-7 cells. The effects of the D61G mutation on tumourigenesis and malignant behaviours, such as cell adhesion, proliferation, migration and invasion, were examined. Potential underlying molecular mechanisms, i.e., activation of the Gab1-Ras-Erk axis, were also examined.
Results: In vitro experiments revealed that tumour adhesion, proliferation, migration and invasion were significantly increased in the SHP2 D61G mutant groups. Consistently, in vivo experiments also showed that the tumour sizes and weights were increased significantly in the SHP2 D61G-MB231 group (p < 0.001) in association with tumour metastasis. Mechanistically, the PTPN11 mutation resulted in activation of the Ras-ErK pathway. The binding between Gab1 and mutant SHP2 was significantly increased.
Conclusion: Mutant SHP2 significantly promotes tumour migration and invasion at least partially through activation of the Gab1-Ras-Erk axis. This finding could have direct implications for breast cancer therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.